• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

CME/CE Quiz

Publication
Article
Supplements and Featured PublicationsUpdate on the Diagnosis and Treatment of Gout
Volume 11
Issue 15 Suppl

Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2 Category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours that he/she actually spends in the educational activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.

Continuing Pharmacy Education AccreditationPharmacy Times/Ascend Media Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-999-05-021-H04.

InstructionsAfter reading "Update on the Diagnosis and Treatment of Gout," complete the program evaluation and select the 1 best answer to each of the following questions. A statement of continuing education hours will be mailed to those who successfully complete (with a minimum score of 70%) the examination at the conclusion of the program.

1. Hyperuricemia is most often the result of:

b) inefficient excretion of uric acid by the kidneys

d) high cellular turnover

2. Gout is more prevalent among:

b) European Americans than African Americans

d) persons < 65 years of age than those > 65 years of age

3. The metabolic syndrome is present in up to what percentage of gout patients?

b) 55%

d) 92%

4. Increased risk of gout is associated with:

b) diuretic use

d) insulin therapy

5. The risk of gout is greater for those with diets high in:

b) purine-rich vegetables

d) low-fat dairy products

6. All of the following may be reasons for the increasing prevalence of gout in the United States except:

b) increased use of diuretics

d) increased prevalence of end-stage renal disease

7. The gold standard for a gout diagnosis is:

b) radiographic evidence

d) response to colchicine

8. A gouty arthritis attack is most notably characterized by:

b) pain and swelling developing over time

d) warmth or redness of the affected joint

9. Gouty arthritis in the elderly is often mistaken for:

b) psoriatic arthritis

d) Heberden's nodes

10. In women:

b) Arthritis in multiple joints is often the first manifestation of gout.

d) Gouty arthritis tends to be more symmetric than rheumatoid arthritis.

11. Pseudogout can be differentiated from gout with:

b) location of the affected joint

d) identification of calcium pyrophosphate dihydrate crystals

12. Dietary restrictions with weight loss and decreased triglycerides benefit gout patients through:

b) reduced plasma insulin

d) all of the above

13. Which is the treatment of choice for an acute gouty arthritis attack?

b) oral corticosteroids

d) urate-lowering agents

14. The goal of antihyperuricemic therapy in recurrent gout is to lower serum urate concentration to what level?

b) 7-8 mg/dL

d) 5-6 mg/dL

15. Which is usually the urate-lowering agent of choice?

b) sulfinpyrazone

d) losartan

16. In a patient with gout and hyperlipidemia, __________ may be a useful adjunctive urate-lowering agent.

b) estrogen

d) a thiazide diuretic

17. Which of the following statements about the uricosuric agents probenecid and sulfinpyrazone is true?

b) They should be started in low doses.

d) They are indicated for patients with hyperuricemia resulting from overproduction of uric acid.

18. Urate-lowering treatment is cost effective for patients with at least how many gouty flares per year?

b) 2

d) 4

19. Poor social functioning is greater among those with:

b) angina

d) gout

20. Gout outcomes can be improved with:

b) medication compliance

d) all of the above

© 2024 MJH Life Sciences
AJMC®
All rights reserved.